Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech

This article was originally published here

Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device.

The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults using multiple daily injections to deliver high doses of insulin.

Get the full story at our sister site, Drug Delivery Business News.

The post Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply